Table 3.
Current treatments usage in APD and non-APD patients and treatment response
| APD (N = 60) | Non-APD (N = 80) | |
|---|---|---|
| Current PD oral/transdermal treatments (Possible multiple answers) | N = 60 | N = 80 |
| Oral levodopa/carbidopa or benserazide | 55 (92%) | 60 (75%) |
| Oral dopamine agonists | 35 (58%) | 48 (60%) |
| Apomorphine patch | 2 (3%) | 0 |
| Subcutaneous apomorphine rescue injection | 2 (3%) | 0 |
| COMT-inhibitors | 22 (37%) | 6 (8%) |
| MAO-B inhibitors | 14 (23%) | 41 (51%) |
| Amantadine | 6 (10%) | 6 (8%) |
| Missing | 2 (3%) | 0 |
| Current oral/transdermal treatment for PD | N = 60 | N = 80 |
| Patients on only oral/transdermal therapy | 40 (67%) a | 79 (99%) |
| Patients on ongoing DAT | 18 (30%) | 1 (1%) |
| Missing | 2 (3%) | 0 |
| Number of current oral/transdermal treatments | N = 58 | N = 80 |
| 1 | 12 (21%) | 21 (26%) |
| 2 | 19 (33%) | 33 (41%) |
| 3 | 20 (34%) | 24 (30%) |
| 4 | 4 (7%) | 2 (3%) |
| 5 | 3 (5%) | 0 |
| Treatment Response on current treatment (oral/transdermal or DAT) | N = 60 | N = 80 |
| Complete response | 12 (20%) a | 55 (69%) |
| Partial response | 47 (78%) a | 24 (30%) |
| Too early to assess response | 1 (2%) | 1 (1%) |
| Status of DAT in the eligible patients | N = 44 (73%) eligible to DAT | N = 5 (6%) eligible to DAT (1 Missing) |
| Ongoing DAT | 18/44 (41%) | 1/5 (20%) |
| Decided at visit to start DAT | 9/44 (20%) | 0 |
| No DAT | 17/44 (39%) | 3/5 (60%) |
| Type of DAT on 44 eligible APD and on 5 eligible non-APD patients | ||
| DBS | 11 (25%) | 1 (20%) |
| LCIG | 7 (16%) | 0 |
| CSAI | 0 | 0 |
| Reasons APD patients were not using DAT (Possible multiple answers) | N = 17 | |
| Age | 2 (12%) | |
| Patient refusal | 5 (29%) | |
| Patient needs more time to decide | 10 (59%) | |
| Cognitive related issues | 2 (12%) | |
| Comorbidities | 2 (12%) | |
DAT Device Aided Therapy, DBS Deep Brain Stimulation, CSAI Apomorphine SC infusion, LCIG Levodopa-carbidopa intestinal gel, COMT (catechol-O-methyltransferase), MAOB (Monoamine oxidase type B)
aP < 0.001 vs non-APD patients (Chi-square test)